The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016) 12.86

Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes? J Am Coll Surg (2014) 1.38

A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol (2009) 1.16

Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med (2006) 1.05

Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med (2006) 1.00

The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev (2011) 0.98

Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest (2007) 0.97

Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging (2009) 0.89

Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review). Oncol Rep (2014) 0.86

Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging (2005) 0.82

The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. J Korean Med Sci (2014) 0.82

Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. FASEB J (2013) 0.82

Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.82

Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. Curr Oncol (2009) 0.81

Genotoxicity induced by iodine-131 in human cultured lymphocytes. Interdiscip Toxicol (2013) 0.81

Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg (2014) 0.80

Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. J Nucl Med (2012) 0.80

Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy. J Thyroid Res (2014) 0.79

Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning. Eur J Nucl Med Mol Imaging (2008) 0.78

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics (2009) 0.77

Nodular goiter with multiple cystic and solid swellings. Indian J Endocrinol Metab (2012) 0.77

Predicting tumour response. Cancer Imaging (2013) 0.77

Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Semin Nucl Med (2016) 0.77

Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2016) 0.77

Resveratrol sensitizes selectively thyroid cancer cell to 131-iodine toxicity. J Toxicol (2014) 0.77

Resveratrol mitigates genotoxicity induced by iodine-131 in primary human lymphocytes. Radiat Environ Biophys (2013) 0.76

Comparative thyroid gland volume by two methods: Ultrasonography and planar scintigraphy. Pol J Radiol (2012) 0.75

Changes of regulatory T and B cells in patients with papillary thyroid carcinoma after 131I radioablation: a preliminary study. Biomed Res Int (2013) 0.75

Radiosensitive effect of curcumin on thyroid cancer cell death induced by radioiodine-131. Interdiscip Toxicol (2014) 0.75

Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. Radiat Environ Biophys (2017) 0.75

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65

Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol (2012) 3.75

Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab (2010) 1.26

The low utility of pretherapy scans in thyroid cancer patients. Thyroid (2009) 0.78